Cargando…

Point-of-Care Tenofovir Urine Testing for the Prediction of Treatment Failure and Drug Resistance During Initial Treatment for Human Immunodeficiency Virus Type 1 (HIV-1) Infection

BACKGROUND: Viral rebound during antiretroviral treatment (ART) is most often driven by suboptimal adherence in the absence of drug resistance. We assessed the diagnostic performance of point-of-care (POC) tenofovir (TFV) detection in urine for the prediction of viral rebound and drug resistance dur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hermans, Lucas E, Umunnakwe, Chijioke N, Lalla-Edward, Samanta T, Hebel, Shane K, Tempelman, Hugo A, Nijhuis, Monique, Venter, Willem D F, Wensing, Annemarie M J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907515/ https://www.ncbi.nlm.nih.gov/pubmed/36136811 http://dx.doi.org/10.1093/cid/ciac755

Ejemplares similares

Evaluation of a commercial SARS-CoV-2 multiplex PCR genotyping assay for variant identification in resource-scarce settings
por: Umunnakwe, Chijioke N., et al.
Publicado: (2022)

Virological suppression and clinical management in response to viremia in South African HIV treatment program: A multicenter cohort study
por: Hermans, Lucas E., et al.
Publicado: (2020)

Predictors of Treatment Adherence and Virological Failure Among People Living with HIV Receiving Antiretroviral Therapy in a South African Rural Community: A Sub-study of the ITREMA Randomised Clinical Trial
por: Gumede, Siphamandla B., et al.
Publicado: (2023)

Tenofovir-Diphosphate in Dried Blood Spots vs Tenofovir in Urine/Plasma for Oral Preexposure Prophylaxis Adherence Monitoring
por: Niu, Xin, et al.
Publicado: (2022)

Understanding adherence in virally suppressed and unsuppressed human immunodeficiency virus-positive urban patients on second-line antiretroviral treatment
por: Gumede, Siphamandla B., et al.
Publicado: (2020)

Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide for Human Immunodeficiency Virus Preexposure Prophylaxis at a Boston Community Health Center
por: Marcus, Julia L, et al.
Publicado: (2021)

A randomized study of intensified antiretroviral treatment monitoring versus standard-of-care for prevention of drug resistance and antiretroviral treatment switch
por: Hermans, Lucas E., et al.
Publicado: (2022)

Human Immunodeficiency Virus gag and protease: partners in resistance
por: Fun, Axel, et al.
Publicado: (2012)

Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK Studies
por: Squires, Kathleen, et al.
Publicado: (2017)

Is Emtricitabine-Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis for the Prevention of Human Immunodeficiency Virus Infection Safer Than Aspirin?
por: Kojima, Noah, et al.
Publicado: (2016)

Tenofovir Alafenamide Plasma Concentrations Are Reduced in Pregnant Women Living With Human Immunodeficiency Virus (HIV): Data From the PANNA Network( )
por: Bukkems, Vera E, et al.
Publicado: (2021)

Association of Hepatitis B Core-Related Antigen and Antihepatitis B Core Antibody With Liver Fibrosis Evolution in Human Immunodeficiency Virus-Hepatitis B Virus Coinfected Patients During Treatment With Tenofovir
por: Cruchet, Romuald, et al.
Publicado: (2020)

Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate
por: Huhn, Gregory D, et al.
Publicado: (2019)

A Randomized Switch From Nevirapine-Based Antiretroviral Therapy to Single Tablet Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed Human Immunodeficiency Virus-1-Infected Rwandans
por: Collins, Sean E., et al.
Publicado: (2016)

Renal Safety of Long-term Tenofovir Disoproxil Fumarate Treatment in Patients With Chronic Hepatitis B
por: Woldemedihn, Gezahegn M, et al.
Publicado: (2023)

Hepatic Steatosis and Weight Gain During the Coronavirus Disease 2019 Pandemic Among People With Human Immunodeficiency Virus: Impact of Therapy With Tenofovir Alafenamide
por: Santos, Marta, et al.
Publicado: (2023)

Antiretroviral therapy uptake and predictors of virological failure in patients with HIV receiving first-line and second-line regimens in Johannesburg, South Africa: a retrospective cohort data analysis
por: Gumede, Siphamandla Bonga, et al.
Publicado: (2022)

High Rates of Transmission of Drug-resistant HIV in Aruba Resulting in Reduced Susceptibility to the WHO Recommended First-line Regimen in Nearly Half of Newly Diagnosed HIV-infected Patients
por: Hofstra, L. Marije, et al.
Publicado: (2017)

Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study
por: Huhn, Gregory D, et al.
Publicado: (2019)

Training Internal Medicine Residents to Provide Care and Treatment for Human Immunodeficiency Virus-1-Infected Patients
por: Valenti, Sharon, et al.
Publicado: (2019)

Changes in Body Mass Index and Atherosclerotic Disease Risk Score After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide
por: Schafer, Jason J, et al.
Publicado: (2019)

The Effect of Rosuvastatin on Markers of Immune Activation in Treatment-Naive Human Immunodeficiency Virus-Patients
por: Weijma, Robyn G. M., et al.
Publicado: (2015)

First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial
por: Waalewijn, Hylke, et al.
Publicado: (2023)

Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment-Experienced Patients
por: Schafer, Jason J, et al.
Publicado: (2020)

Genital Shedding of Resistant Human Immunodeficiency Virus-1 Among Women Diagnosed With Treatment Failure by Clinical and Immunologic Monitoring
por: Graham, Susan M., et al.
Publicado: (2016)

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial
por: Orkin, Chloe, et al.
Publicado: (2020)

Switch to Rilpivirine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012–2014
por: Cazanave, Charles, et al.
Publicado: (2015)

Antibody Responses After Analytic Treatment Interruption in Human Immunodeficiency Virus-1-Infected Individuals on Early Initiated Antiretroviral Therapy
por: Stephenson, Kathryn E., et al.
Publicado: (2016)

Lateral Flow Urine Lipoarabinomannan Assay for Diagnosis of Active Tuberculosis in Adults With Human Immunodeficiency Virus Infection: A Prospective Cohort Study
por: Songkhla, Munjit Na, et al.
Publicado: (2019)

Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Patients With HIV-1 Infection and Ongoing Substance Use Disorder: The BASE Study
por: Havens, Joshua P, et al.
Publicado: (2023)

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate for Nonoccupational HIV-1 Postexposure Prophylaxis: A Prospective Open-Label Trial (DORAVIPEP)
por: Inciarte, Alexy, et al.
Publicado: (2023)

Treatment Outcomes Among Older Human Immunodeficiency Virus-Infected Adults in Nigeria
por: Agaba, Patricia A., et al.
Publicado: (2017)

Substance Use Treatment Utilization Among Women With and Without Human Immunodeficiency Virus
por: Fujita, Ayako W, et al.
Publicado: (2022)

Decreased All-Cause and Liver-Related Mortality Risk in HIV/Hepatitis B Virus Coinfection Coinciding With the Introduction of Tenofovir-Containing Combination Antiretroviral Therapy
por: van Welzen, Berend J, et al.
Publicado: (2020)

Determinants of Antiretroviral Treatment Success and Adherence in People With Human Immunodeficiency Virus Treated for Tuberculosis
por: De Castro, Nathalie, et al.
Publicado: (2022)

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial( )
por: Osiyemi, Olayemi, et al.
Publicado: (2022)

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
por: Kawuma, Aida N., et al.
Publicado: (2023)

Urine Tenofovir Levels Measured Using a Novel Immunoassay Predict Human Immunodeficiency Virus Protection
por: Stalter, Randy M, et al.
Publicado: (2020)

Changes in Quality of Sleep, Mood, and Other Neuropsychiatric Symptoms After Switching Dolutegravir/Lamivudine/Abacavir to Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Randomized Study of People With Human Immunodeficiency Virus With Poor Sleep Quality: GESIDA 10418
por: Cabello-Úbeda, Alfonso, et al.
Publicado: (2022)

Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide
por: Lalley-Chareczko, Linden, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jmr64btl7fun9mhlgpk0aag9cu